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Abstract
Background:  Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are
approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices
amongst these drugs, one should consider their clinical merits and their economic implications.
Methods: Each drug's short-term efficacy was estimated based on independent Cochrane reviews
of the clinical trials. Long-term clinical and economic outcomes were estimated using the
Assessment of Health Economics in Alzheimer's Disease (AHEAD) model.
Results: While all treatments reduced the need for full-time care, only galantamine and donepezil
10 mg reduced the overall management costs of AD patients. The somewhat greater cognitive
effect provided over six months by galantamine leads to the longest estimated delay before full-time
care is required and, consequently to lower overall costs, with savings estimated at between $323
and $4,246.
Conclusion: Although there is uncertainty in estimated results, the best information currently
available suggests that the first choice for treatment of AD should be galantamine. These results
should be interpreted with caution, however, as results are not based on direct comparisons
among the drugs and the differences emerging from meta-analyses of the trials are relatively small.
Background
The number of Canadians with Alzheimer's disease (AD)
is expected to rise to over half a million by 2031 [1], and
the costs of caring for these patients have been shown to
be heavily dependent on disease severity [2,3], with a
recent estimate of $9,451 (1996 Canadian dollars) per
year for patients with mild AD to $36,794 per year for
patients with severe AD [3].
Although the adoption of cholinesterase inhibitors for the
treatment of AD has not met with unconditional endorse-
ment in Canada [4,5], this was the only class of anti-
dementia drugs recommended by the Canadian Consen-
sus Conference on Dementia [6] and is becoming the
standard of care. It is hoped that the short-term benefits
observed in clinical trials lasting a few months [7-9] will
translate to slower decline over the subsequent years.
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No studies have yet fully documented the long-term eco-
nomic implications of treatment with these drugs, but
four [10-13] have estimated what they might be in Can-
ada using models of the course of the illness. Similar anal-
yses have also been carried out for other countries [14-
21]. Although each of the Canadian analyses predicted
delayed disease progression and associated savings, the
lack of a common methodology and contrasts with other
active treatments mean that the results are not directly
comparable and, thus, do not help in making choices
among the drugs.
To inform therapeutic decisions, we undertook a compar-
ison of the three cholinesterase inhibitors approved for
use in Canada: donepezil, rivastigmine and galantamine.
We sought to remove extraneous effects due to disparate
modeling approaches by using a common, published and
validated, analytic framework: the Assessment of Health
Economics in Alzheimer's Disease (AHEAD) model [22].
To ensure balanced estimates of the efficacy of these
drugs, particularly given our source of funding, we based
our calculations on the independent reviews published by
the Cochrane Collaboration [23-25].
Methods
The AHEAD Model
The AHEAD model simulates the course of AD according
to the patient's characteristics at a given point in time
[13,22]. This is done by forecasting the time until each
patient with AD requires full-time care (FTC) – the con-
sistent requirement for a significant amount of caregiving
and supervision for the greater part of the day, regardless of
the locus of care and who the caregiver is. These forecasts
are derived by estimating the failure-time curves that
result from the corresponding time-dependent hazards.
The hazards are calculated using equations that depend
on the presence of extrapyramidal symptoms (EPS), the
presence of psychotic symptoms, age at onset, duration of
illness and cognitive status. The model also forecasts sur-
vival, which depends on sex, EPS, duration of illness and
cognitive status. The required equations were derived
from published long-term follow up data of patients with
AD [26].
The model considers four states: 1) not yet requiring FTC
(pre-FTC), 2) requiring FTC but still living in the commu-
nity (FTC community), 3) requiring FTC and institutional-
ized (FTC institution), or 4) dead. The model uses
individual patient data as inputs into the predictive equa-
tions, and the individual results are then aggregated into
an overall forecast for the entire cohort. Comparisons
between treatment scenarios are achieved by re-comput-
ing the failure-time curves for the same patients under
each treatment scenario.
The cognitive portion of the Alzheimer Disease Assess-
ment Scale (ADAS-cog) [27] is used as the measure of cog-
nition in this model as cognitive outcomes of trials are
typically reported using this measure. Cognitive status
after six months (C6) in the absence of pharmacologic
treatment is forecast using a regression equation based on
baseline cognitive status (C0). The equation, derived from
patient-level data on untreated participants in three clini-
cal trials [28-30] was C6 = -0.54+1.10 C0 (the 95% confi-
dence intervals for the coefficients were -1.94 to 0.97 for
the intercept term, and 1.05 to 1.15 for the slope term).
An increase in the score reflects deterioration in cognitive
functioning.
Along with the duration of FTC and economic outcomes,
the model calculates quality adjusted life years (QALY)
remaining by assigning quality "weights" to each state.
Values of 0.603 for pre-FTC, 0.338 for FTC regardless of
location of care, and 0 for death were derived from pub-
lished data [31]. A single value was used for FTC as the
study on which quality weights were based found that set-
ting of care did not have an independent effect on out-
comes [31].
If one treatment is estimated to increase health benefits
but also the costs relative to the next most effective treat-
ment, the model calculates the incremental cost-effective-
ness ratio in terms of the net cost per QALY gained (both
discounted). Pair-wise comparisons, even for treatments
otherwise dominated, are also reported here since these
may be relevant in settings where the dominant treatment
cannot be used.
Results are forecast over ten years from the start of treat-
ment because by that time all survivors require FTC. A rate
of 3% per annum was used to discount costs and health
benefits occurring after year one.
Population for Analyses
To provide a common population of patients for these
analyses, the clinical and demographic characteristics of
participants in a recent clinical trial [30] were used.
Among these 918 patients, who should be broadly repre-
sentative of those for whom the drugs are indicated,
64.9% were female and the mean age was 77.2 years.
ADAS-Cog scores ranged from 10 to 62, with the mean
ADAS-cog score at baseline being 28.9 and the first and
third quartiles of the distribution being 21 and 36, respec-
tively. Psychotic symptoms were exhibited in 32.4% of the
patient population, 7.5% had EPS, 8.9% had early onset
of disease, and the mean duration of illness was just over
four years. In the absence of pharmacologic treatment, it
was estimated that after six months, the average ADAS-cog
score would deteriorate to 31.3.BMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/6
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Treatment Efficacy
Computations for each treatment were based on the cog-
nitive effects reported in the Cochrane reviews – formal
meta-analyses of the randomized clinical trials assessing
efficacy and safety of these drugs. For each drug and dose,
the reviews reported point estimates and 95% confidence
intervals (CI) for the weighted difference in mean cogni-
tive change comparing the treatment to placebo using
intention-to-treat analysis with last observation carried
forward (LOCF) methods used for patients dropping out
of the trial (Table 1). While it is possible that the LOCF
method may slightly overestimate the cognitive effects of
treatment if withdrawals from the trial are higher with
treatment than without (as patients cognition, on average,
should decline between the time of withdrawal and the
end of the study), these were the only data available for all
three active treatments and the same methods were used
for all.
These estimates were used to determine the change in cog-
nition expected with each treatment and dose over six
months for each patient in the model population. Two
approaches were taken to make these predictions. For the
main analyses, the most direct approach was used: the
Cochrane estimated mean difference from placebo (∆C)
was applied to the intercept term in the regression equa-
tion that describes progression without treatment: C6 = (-
0.54+ ∆C) + 1.10 C0. This implies that treatment has a
constant absolute effect on cognition, regardless of base-
line ADAS-cog – thus termed the 'constant effect' analysis.
To consider possible dependency of the treatment effect
on the baseline disease severity [32,33], a second, 'varia-
ble effect", approach was used in sensitivity analyses. For
this approach, a term was added to the regression equa-
tion reflecting the interaction between treatment (T) and
baseline ADAS-cog score: C6 = -0.54+1.10 C0+ β·T·C0.
The coefficient β was estimated for each treatment by solv-
ing the equation at the mean baseline ADAS-cog scores
reported for each treatment arm in the trials [28-30], [34-
36]: β = ∆C/  (Table 1).
In both the constant and variable effect analyses, the treat-
ment effect was applied only to patients who were pre-
dicted to complete the first six months of therapy. For
those predicted to withdraw from therapy, the rates of
cognitive change expected without treatment were
applied. The likelihood of completing the first six months
of treatment was predicted for each patient by adjusting
the base withdrawal rate incorporated in AHEAD accord-
ing to a treatment-specific factor derived from the
Cochrane reviews by calculating the ratio of treatment to
placebo withdrawals (Table 1). For example, if treatment
were associated with a relative risk of withdrawing equal
to 2, and the base withdrawal risk for a patient were 10%,
then with treatment, the withdrawal risk would be 20% (2
× 10%). The overall base withdrawal rate in AHEAD was
16%.
Although there is evidence that these drugs may have an
impact on psychotic symptoms [37], this aspect was not
included in these analyses because those data were not
reported in the Cochrane reviews for all treatments.
Evidence that treatment affects survival is not yet available
so mortality was assumed to be equal for all therapeutic
options. This equivalence was ensured by calculating mor-
tality with all three treatments using the ADAS-cog scores
had the patients remained untreated.
Costs
Costs are reported in 2001 Canadian dollars and are deter-
mined from the perspective somewhat broader than that
of a comprehensive payer. For example, informal costs
such as in-home personal care were included. Costs were
estimated based primarily on resource use data from the
clinical assessment portion of a follow-up survey of the
Canadian Study of Health and Aging [38] and unit costs
Table 1: Cochrane review data used as the basis for this analysis
Donepezil Rivastigmine Galantamine
Daily dose 5 mg 10 mg 1–4 mg 6–12 mg 16 mg 24 mg
Efficacy* -1.86 -2.90 -0.84 -2.09 -3.10 -3.29
95% CI -2.60, -1.11 -3.65,-2.16 -1.48, -0.19 -2.65, -1.54 -4.13, -2.07 -3.92, -2.65
Beta† -0.071 -0.106 -0.036 -0.091 -0.105 -0.124
95% CI -0.099, -0.042 -0.133, -0.079 -0.067, -0.008 -0.115, -0.067 -0.14 -0.070 -0.147, -0.100
Withdrawal‡ 1.02 1.36 1.01 1.95 1.34 1.51
95% CI 0.78, 1.33 1.10,1.70 0.80, 1.27 1.65, 2.32 0.95, 1.89 1.23, 1.87
* measured in terms of the weighted difference in mean cognitive change on the ADAS-cog comparing treatment to placebo † coefficient for 
variable effect analysis calculated as the efficacy divided by the mean baseline score ‡ relative risk of withdrawing from treatment, compared to 
placebo patients
C0BMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/6
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from the province of Quebec using methods described
elsewhere [13]. The estimates were $432 per patient per
month before FTC is required, $903 monthly for FTC in
the community and $3,931 for a month of FTC in an insti-
tution. Based on published data, it is expected that that
almost three-quarters (73.5%) of patients requiring FTC
will be institutionalized [3,13]. No event cost was
assigned to the transition to FTC or to death. The daily
cost of each cholinesterase inhibitor was set at $4.59.
Daily treatment cost was independent of dose, reflecting
current pricing practices for cholinesterase inhibitors in
Canada. Patients predicted to discontinue treatment were
assumed to consume three months of drug. It was con-
servatively assumed that to maintain the cognitive benefit
obtained, all those who do not withdraw in the first six
months, require continued treatment until FTC is needed.
Once this happens, pharmacologic treatment was
assumed to end for all patients. Treatment discontinua-
tion prior to needing FTC was not considered, although
one might expect that in addition to no longer incurring
treatment costs, benefits attained through treatment prior
to discontinuation may be lost over time.
Sensitivity Analyses
Sensitivity analyses were performed on key inputs and
assumptions. To reflect the uncertainty in the relative cog-
nitive effect of each treatment, univariate sensitivity anal-
yses were run using the upper and lower 95% confidence
interval bounds for each drug's treatment effect. Health
utility and cost inputs were varied and a potential survival
benefit based on the cognitive effect was explored. Sensi-
tivity analyses were also conducted assuming lower dis-
continuation rates, as the Cochrane reviews present
evidence of modified dose-escalation regimens for each of
the three therapies leading to significantly fewer drop-outs
over the trial periods. Finally, all analyses were rerun using
discount rates of 0%, 5% and 10%.
Apart from univariate analyses of each factor, multivariate
probabilistic analyses were also carried out. The ranges
over which each factor was changed in the multivariate
analyses are displayed in Table 2.
Results
With no pharmacologic treatment, the patients modeled
are expected to survive, on average, an additional 60.3
months and to require FTC after an estimated 38.4
months. The average total cost of caring for these patients
over the modeling period is $84,869 ($76,806
discounted).
Main Analysis
In the constant effect analysis, all treatments reduce the
time FTC is required relative to no treatment, but only the
higher dose of donepezil and both doses of galantamine
reduce costs (Table 3). As these three treatment options
also provide greater effects, they dominate the others (i.e.,
have greater health effects and lead to lower overall costs).
Both doses of galantamine also dominate the higher dose
of donepezil. The only cost-effectiveness scenario
amongst active treatments exists with donepezil 5 mg,
which has a superior health effect compared to rivastig-
mine 6–12 mg, but is more expensive, with incremental




In the variable effect analyses, the most notable change is
that the lower dose of galantamine was no longer domi-
nant over donepezil 10 mg: now a nominal reduction of
FTC need (0.1%) is obtained at an incremental cost of $3
per patient ($13,338 per QALY gained).
ADAS-Cog change
When the upper limits of the 95% confidence interval of
the weighted difference in mean ADAS-cog change are
used, the relative positions of the treatments do not
change, but when the lower limits are used, the higher
dose of donepezil dominates the lower one of galan-
tamine. This results from the tighter interval around the
Table 2: Inputs for the multivariate sensitivity analyses
Parameter Type Mid-Point Range
Pre-FTC cost Triangular $432 $279 – $584
FTC in Community cost Triangular $903 $584 – $1,222
FTC in Institution cost Triangular $3,931 $2,543 – $5,319
% FTC in Institution Triangular 73.5% 47% – 100.0%
Cognitive effect Normal† See Table 1 for means and ranges
Withdrawal Risk Normal† of Log RR‡ See Table 1 for means and ranges
† all normal distributions were bounded at their two standard deviations ‡ relative risk of withdrawing from treatment, compared to untreated 
patientsBMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/6
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donepezil estimate (Sensitivity analyses reported in the
following sections were also carried out for the variable
effect analyses. Results available from the authors.).
Treatment Withdrawal
The confidence intervals of the withdrawal adjustment
factors for the lower doses of all three cholinesterase
inhibitors included a value of one (i.e., withdrawal no dif-
ferent than with placebo), and there is some evidence that
slower titration regimens might result in lower discontin-
uation rates even for the higher doses of these drugs. An
analysis was therefore undertaken assuming that the with-
drawal factor was one for all treatments. The only result-
ing change in position of the treatments was that higher
dose rivastigmine dominated the lower dose of donepezil
under these conditions.
Mortality
Although there is no evidence to indicate that cholineste-
rase inhibitors improve survival, if the cognitive benefits
are allowed to translate to mortality reductions, all treat-
ments are predicted to increase costs relative to no treat-
ment because the additional survival incurs further costs.
This does not affect, however, the position of the active
treatments relative to one another.
FTC Costs
Changes in this parameter affect the results relative to no
treatment, but not the comparisons among treatment
options.
Health Utilities
Changes in health utility estimates of 25% in either direc-
tion had no appreciable impact on the comparisons
among cholinesterase inhibitors.
Discount Rate
Alternative discount rates also had only a small influence
on overall results, and did not influence the relative
ranking of active treatments. For example, galantamine 24
mg resulted in net savings ranging from $249 to $4,705 if
no discounting were applied. If a 10% rate were used, sav-
ings, although lower, were still attained in all cases, rang-
ing from $201 to $3,414.
Multivariate Analysis
The results of the multivariate sensitivity analyses largely
confirm the main ones. The higher dose of rivastigmine is
always dominated by the higher dose of galantamine and
nearly always (96.1%) by the lower dose of galantamine.
The higher dose of donepezil is only dominated in about
half the scenarios (55.6%) with respect to the lower dose
of galantamine, and is dominated by the higher dose of
galantamine most of the time (69.4%).
Discussion
The results of these analyses, which incorporate the best
currently available information, suggest that galantamine
should be the first choice for treatment of patients with
AD. Using the AHEAD model to extend independently
published short-term efficacy estimates, galantamine is
predicted to lead to a somewhat longer delay of the need
for FTC and ultimately lower costs, thus dominating other
treatment options. The second best choice appears to be
donepezil.
These results need to be placed in context. To date, ade-
quate direct comparisons of these drugs in clinical trials
are lacking, and the Cochrane meta-analyses show rela-
tively small differences among the treatments. Further-
more, it is impossible to ensure that differences among
the study populations and trial protocols are fully
accounted for, even in the variable effect analysis. It
Table 3: Principle outcomes of the constant effect analyses*
Comparator
Treatment No drug treatment Rivastigmine Donepezil Galantamine
1–4 mg 6–12 mg 5 mg 10 mg 16 mg
Rivastigmine
1–4 mg 3.0%** $2,880† $224,222¶
6–12 mg 5.8% $514 $36,161 3.0% -$2,370 Dominant
Donepezil
5 mg 6.6% $1,032 $36,161 3.7% -$1,849 Dominant 0.8% $522 $158,875
10 mg 9.5% -$811 Dominant 6.7% -$3,692 Dominant 3.9% -$1,321 Dominant 3.1% -$1,843 Dominant
Galantamine
16 mg 10.2% -$1,134 Dominant 7.5% -$4,015 Dominant 4.6% -$1,644 Dominant 3.9% -$2,166 Dominant 0.8% -$323 Dominant
24 mg 10.3% -$1,366 Dominant 7.6% -$4,246 Dominant 4.7% -$1,876 Dominant 4.0% -$2,398 Dominant 0.9% -$555 Dominant 0.1% -$232 Dominant
* for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring 
FTC † net costs ¶ incremental cost per QALY gainedBMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/6
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should also be kept in mind that treatment effects for all
drugs were based on populations enrolled in clinical tri-
als, which may not be representative of the AD population
in Canada as a whole. Until long-term data become avail-
able for patients treated in the community, however, it is
difficult to determine how much different the clinical
effectiveness and tolerability of these drugs will be in
actual practice relative to a clinical trial setting. Finally,
long-term forecasts are made based on the results of trials
that lasted only six months. Longer-term data are emerg-
ing [39-44], but these are even less comparative as most
are open-label extensions of trials where most patients
were switched to active treatment regardless of original
assignment.
Despite these sources of uncertainty, the results are main-
tained over most sensitivity analyses. In the multivariate
probabilistic sensitivity analyses, galantamine remained
dominant in the vast majority of scenarios.
Other factors not taken into account in this analysis
should also be considered as data become available. Of
note, these analyses limit the effect of these drugs to cog-
nition. There is growing evidence that aspects other than
cognition may be improved by treatment [30,37,45,46].
For example, in one double-blind placebo-controlled trial
that measured behavioral symptoms [30], patients rand-
omized to either galantamine 16 mg or 24 mg showed sig-
nificant behavioral benefits over placebo-treated patients.
This aspect of treatment was not included in the analysis,
however, as appropriate data from randomized trials were
not available for all three cholinesterase inhibitors under
evaluation.
Caregiver burden has also not been considered [47-49] in
this analysis. In Canada, the most recent estimate of car-
egiving costs places these at between $400 and $700 per
patient, per month, depending on the stage of the disease
[3] and the recent Canadian Consensus Conference on
Dementia acknowledged the significant burden placed on
caregivers of the demented elderly [6]. Data that would
allow inclusion of caregiver burden and its attendant costs
are beginning to appear. For example, the effects of galan-
tamine on caregiver time were assessed in a 6-month ran-
domized, placebo-controlled trial [50]. Caregivers of
patients on galantamine spent less time supervising
patients than caregivers of patients on placebo (by
between 82 and 98 minutes per day). Caregivers of treated
patients also spent between 38 and 61 minutes less per
day assisting patients with activities of daily living. Inclu-
sion of this aspect would add to the completeness of the
analysis, and likely accentuate current results. As compa-
rable data for donepezil and rivastigmine are currently
lacking, however, a conservative approach was taken and
caregiver burden was left out of the analysis.
It is also worth noting that individuals may respond to
one drug better than another in ways not reflected by cal-
culations based on the average effects in a population,
such as those used in this analysis. Thus, treatment should
be tailored to each patient, with careful monitoring of
response and tolerability dictating the final treatment
course.
Conclusions
With the number of Canadians with AD increasing and
health care resources already stretched, it is becoming
increasingly important to evaluate therapeutic alternatives
for these patients to provide a rational basis for treatment
decisions. These analyses indicate that galantamine
should be the first choice for treatment of AD, but it must
be conceded that the information is less than optimal and
differences emerging from meta-analyses of the clinical
trials are relatively small. Further comparative experience
over the next several years should provide a more
definitive assessment of the long-term health and eco-
nomic consequences of these drugs. Large-scale head-to-
head clinical trials between the available cholinesterase
inhibitors would provide the evidence base for a more
authoritative conclusion on the relative effectiveness and
cost-effectiveness of these drugs.
Finally, as new treatments emerge, these will also need to
be assessed, even before complete data are available. The
AHEAD model provides a framework for these
assessments.
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